Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
A recent study demonstrated remarkable discrepancy between the relapse-free survival (RFS) and overall survival (OS) after pulmonary metastasectomy (PM) in the current era. As the RFS may not be a suitable parameter after PM, a more suitable parameter is needed for PM as a surrogate marker for OS.
A total of 134 consecutive patients who underwent PM were retrospectively analyzed. In the present study, we introduced a new endpoint, time to local treatment failure (TLTF). This endpoint was defined as the time interval between the first PM and the first untreatable recurrence by local treatment with curative intent or death due to any cause. We analyzed the correlation between the RFS and OS and between the TLTF and OS to validate whether or not the TLTF is a better parameter than the RFS after PM.
Thus far, 78 patients have experienced relapse. Of these, 37 patients (47%) underwent local therapy with curative intent, 29 of whom are alive without local treatment failure. The 5-year OS, RFS and TLTF were 70.9%, 36.5%, and 57.6%, respectively. The concordance proportions for the RFS and OS and for the TLTF and OS were 0.634 and 0.851 for all patients, respectively. The Spearman’s rank correlation coefficient for the RFS and OS was 0.639, while that for the TLTF and OS was 0.875.
The TLTF may be a good surrogate parameter for the OS after PM in the current era.
Higashiyama M, Tokunaga T, Nakagiri T et al (2015) Pulmonary metastasectomy: outcomes and issues according to the type of surgical resection. Gen Thorac Cardiovasc Surg 63:320–330 CrossRef
Kanzaki R, Higashiyama M, Fujiwara A et al (2010) Outcome of surgical resection of pulmonary metastasis from urinary tract transitional cell carcinoma. Interact CardioVasc Thorac Surg 11:60–64 CrossRef
Kanzaki R, Inoue M, Minami M et al (2014) Surgery for pulmonary malignancies in patients with a previous history of head and neck squamous cell carcinoma. Surg Today 44:646–652 CrossRef
Kanzaki R, Kimura T, Kawamura T et al (2017) Surgery for malignant pulmonary nodules in patients with a history of oesophageal cancer. Interact CardioVasc Thorac Surg 24:418–424
Thomford NR, Woolner LB, Clagett OT (1965) The surgical treatment of metastatic tumors in the lungs. J Thorac Cardiovasc Surg 49:357–363
Kondo H, Okumura T, Ohde Y et al (2005) Surgical treatment for metastatic malignancies. Pulmonary metastasis: indications and outcomes. Int J Clin Oncol 10:81–85 CrossRef
Kanzaki R, Inoue M, Kimura T et al (2017) Role of pulmonary metastasectomy in colorectal cancer in the era of modern multidisciplinary therapy. Surg Today 47:1111–1118 CrossRef
Kanzaki R, Higashiyama M, Oda K et al (2011) Outcome of surgical resection for recurrent pulmonary metastasis from colorectal carcinoma. Am J Surg 202:419–426 CrossRef
Kanzaki R, Higashiyama M, Fujiwara A et al (2011) Long-term results of surgical resection for pulmonary metastasis from renal cell carcinoma: a 25-year single-institution experience. Eur J Cardio Thorac Surg 39:167–172 CrossRef
Matsuguma H, Yoshino I, Ito H et al (2011) Is there a role for pulmonary metastasectomy with a curative intent in patients with metastatic urinary transitional cell carcinoma? Ann Thorac Surg 92:449–453 CrossRef
Chudgar NP, Brennan MF, Tan KS et al (2017) Is repeat pulmonary metastasectomy indicated for soft tissue sarcoma? Ann Thorac Surg 104:1837–1845 CrossRef
Treasure T, Mineo T, Ambrogi V et al (2015) Survival is higher after repeat lung metastasectomy than after a first metastasectomy: too good to be true? J Thorac Cardiovasc Surg 149:1249–1252 CrossRef
Signoretti S, Flaifel A, Chen Y-B et al (2018) Renal cell carcinoma in the era of precision medicine: from molecular pathology to tissue-based biomarkers. J Clin Oncol 36:3553–3559 CrossRef
Abufaraj M, Dalbagni G, Daneshmand S et al (2018) The role of surgery in metastatic bladder cancer: a systematic review. Eur Urol 73:543–557 CrossRef
Martin-Liberal J, Perez E, Garcia Del Muro X (2019) Investigational therapies in phase II clinical trials for the treatment of soft tissue sarcoma. Expert Opin Investig Drugs 28:39–50 CrossRef
Oba M, Hasegawa K, Matsuyama Y et al (2014) Discrepancy between recurrence-free survival and overall survival in patients with resectable colorectal liver metastases: a potential surrogate endpoint for time to surgical failure. Ann Surg Oncol 21:1817–1824 CrossRef
Hasegawa H, Ninomiya M, Honbou T et al (2011) A case of long-term survival by combined modality therapy for liver and pulmonary metastasis of rectal cancer. Jpn J Cancer Chemother 38:2310–2312
Hiraki T, Gobara H, Iguchi T et al (2014) Radiofrequency ablation as treatment for pulmonary metastasis of colorectal cancer. World J Gastroenterol 20:988–996 CrossRef
Lodeweges JE, Klinkenberg TJ, Ubbels JF et al (2017) Long-term outcome of surgery or stereotactic radiotherapy for lung oligometastases. J Thorac oncol 12:1442–1445 CrossRef
Gwilliam B, Keeley V, Todd C et al (2015) Development of prognosis in palliative care study (PiPS) predictor models to improve prognostication in advanced cancer: prospective cohort study. BMJ Support Palliat Care 5:390–398 CrossRef
- Proposal of a Useful Surrogate Endpoint of the Overall Survival in Patients Undergoing Pulmonary Metastasectomy: The Time to Local Therapy Failure
- Springer International Publishing
World Journal of Surgery
Official Journal of the International Society of Surgery/Société Internationale de Chirurgie
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
Neu im Fachgebiet Chirurgie
Mail Icon II